A phase 2 study of rituximab, cyclophosphamide, bortezomib and dexamethasone (R-CyBorD) in relapsed low grade and mantle cell lymphoma

• Published in: Leukemia & lymphoma Vol. 59; no. 9; pp. 2128 - 2134
• Main Authors: Sonbol, Mohamad Bassam, Hilal, Talal, Dueck, Amylou C., Rosenthal, Allison C., Conley, Christopher R., Kosiorek, Heidi E., Ginos, Brenda F., Gano, Katherine M., Nichols, Craig S., Leis, Jose F., Johnston, Patrick B., Habermann, Thomas M., Northfelt, Donald W., Bergsagel, Peter Leif, Inwards, David J., Witzig, Thomas E., Ansell, Stephen M., Reeder, Craig B.
• Format: Journal Article
• Language: English
• Published: United States Taylor & Francis 02-09-2018
• Subjects: CyBorD; follicular lymphoma; mantle cell lymphoma; Non-Hodgkin lymphoma; phase II trials; Non-Hodgkin lymphoma; CyBorD; mantle cell lymphoma; follicular lymphoma; phase II trials
• ISSN: 1042-8194; 1029-2403
• DOI: 10.1080/10428194.2017.1416368

In this phase 2 trial, we sought to evaluate the efficacy and safety of rituximab, cyclophosphamide, bortezomib, and dexamethasone (R-CyBorD) in patients with low-grade NHL. The regimen included rituximab on day 1 with weekly cyclophosphamide, dexamethasone, and bortezomib 1.3 mg/m
2
IV in a 28-day cycle. Twenty one patients were enrolled on the study. Median age was 69 years (range 51-80) and 17 (81%) patients had two or more prior treatments. Histologies included FL (n = 8), MCL (n = 8), and LPL/WM (n = 5). Hematologic toxicity and peripheral sensory neuropathy were the most common adverse events. With a median follow-up of 38.1 months, ORR was 13/21 (62%), with 4 (19%) CR. The ORR was 7/8 (88%) in FL and was 4/5 (80%) in LPL/WM. Median PFS and OS were 11.6 months and 54.8 months, respectively. R-CyBorD is an effective regimen in relapsed FL and LPL/WM patients with an acceptable safety profile.